Bacteraemic and non-bacteraemic/urinary antigen-positive pneumococcal community-acquired pneumonia compared

被引:0
|
作者
S. P. van Mens
A. M. M. van Deursen
S. C. de Greeff
H. E. de Melker
L. M. Schouls
A. van der Ende
M. J. M. Bonten
E. A. M. Sanders
B. J. M. Vlaminckx
机构
[1] St. Antonius Hospital,Department of Medical Microbiology and Immunology
[2] University Medical Center Utrecht,Medical Microbiology
[3] Linnaeus Institute,Paediatric Immunology and Infectious Diseases
[4] Wilhelmina Children’s Hospital,Medical Microbiology
[5] National Institute for Public Health and the Environment,Netherlands Reference Laboratory for Bacterial Meningitis
[6] Academic Medical Center Amsterdam,undefined
[7] Academic Medical Center Amsterdam,undefined
关键词
Blood Culture; Invasive Pneumococcal Disease; Pneumococcal Pneumonia; Immunocompromising Condition; Heart Valve Disease;
D O I
暂无
中图分类号
学科分类号
摘要
The diagnosis of invasive pneumococcal pneumonia is based mainly on bacteraemia. Episodes without bacteraemia, but with a positive urinary antigen test (UAT), are considered non-invasive. We determined differences in outcome between patients with bacteraemic and non-bacteraemic/UAT-positive pneumococcal community-acquired pneumonia (CAP). Adult patients with clinical and radiological evidence of CAP with blood cultures and UAT tests performed at presentation in three Dutch laboratories between June 2008 and May 2010 were included. Clinical characteristics were retrospectively extracted from hospital records. Overall, 168 patients had non-bacteraemic/UAT-positive pneumococcal CAP and 123 had bacteraemic pneumococcal CAP. The day-30 mortality was 9 % and 13 % for non-bacteraemic/UAT-positive and bacteraemic pneumococcal CAP patients, respectively [risk difference −4 %, 95 % confidence interval (CI) −11 % to +3 %, p = 0.28]. In a multivariable logistic regression model, age ≥65 years, admission to the intensive care unit/coronary care unit (ICU/CCU) and presence of an immunocompromising condition were associated with day-30 mortality. A non-significant association with mortality was found for bacteraemia [odds ratio (OR) 2.21, 95 % CI 0.94–5.21, p = 0.07). No such trend was found for UAT positivity. The median lengths of hospital stay were 8 [interquartile range (IQR) 5–14] and 10 (IQR 6–18) days for non-bacteraemic/UAT-positive and bacteraemic pneumococcal CAP patients, respectively (p = 0.05). As compared to non-bacteraemic/UAT-positive pneumococcal CAP, bacteraemic pneumococcal CAP has a stronger association with day-30 mortality.
引用
收藏
页码:115 / 122
页数:7
相关论文
共 50 条
  • [31] Anemia and community-acquired pneumococcal pneumonia
    S. M. Doshi
    A. M. Rueda
    V. F. Corrales-Medina
    D. M. Musher
    Infection, 2011, 39 : 379 - 383
  • [32] Anemia and community-acquired pneumococcal pneumonia
    Doshi, S. M.
    Rueda, A. M.
    Corrales-Medina, V. F.
    Musher, D. M.
    INFECTION, 2011, 39 (04) : 379 - 383
  • [33] ME1036, a novel carbapenem, with enhanced activity against clinical isolates causing bacteraemic community-acquired pneumonia
    Morrissey, Ian
    Biek, Don
    Janes, Regina
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (01) : 209 - 210
  • [34] Clinical Features And Outcomes Of Patients With Community Acquired Pneumonia With A Positive Pneumococcal Urinary Antigen Test
    Miralles, C.
    Cervera, A.
    Fernandez Fabrellas, E.
    Aguar, M.
    Sanz Herrero, F.
    Briones, M.
    Chiner, E.
    Blanquer, J.
    Herrera, S.
    Climent, M.
    Berraondo, J.
    Novella Sanchez, L.
    Sancho Chust, J. N.
    Landete, P.
    Bravo, R.
    Gil, L.
    Martinez, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [35] Lack of usefulness of the immunochromatographic urinary pneumococcal antigen test in maximizing pneumococcal yield in a community-acquired pneumonia clinical trial
    Vidal, J.
    Adrover, A.
    Garcia-Mendez, E.
    Garcia-Rey, C.
    Dal-Re, R.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 (05) : 562 - 564
  • [36] PNEUMOCOCCAL ANTIGEN PERSISTENCE IN SPUTUM FROM PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA
    BOERSMA, WG
    LOWENBERG, A
    HOLLOWAY, Y
    KUTTSCHRUTTER, H
    SNIJDER, JAM
    KOETER, GH
    CHEST, 1992, 102 (02) : 422 - 427
  • [37] A RISK PREDICTION MODEL TO IMPROVE EFFICIENCY OF PNEUMOCOCCAL URINARY ANTIGEN TESTING IN PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA
    Kim, Priscilla
    Rothberg, Michael B.
    Nowacki, Amy S.
    Yu, Pei-Chun
    Gugliotti, David
    Deshpande, Abhishek
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2022, 37 (SUPPL 2) : 173 - 174
  • [38] Urinary antigen testing in community-acquired pneumonia in adults: an update
    Viasus, Diego
    Calatayud, Laura
    McBrown, Maria V.
    Ardanuy, Carmen
    Carratala, Jordi
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2019, 17 (02) : 107 - 115
  • [39] Community-acquired pneumonia and positive urinary antigen tests: Factors associated with targeted antibiotic therapy
    Mothes, A.
    Leotard, S.
    Nicolle, I.
    Smets, A.
    Chirio, D.
    Rotomondo, C.
    Tiger, F.
    Del Giudice, P.
    Perrin, C.
    Neri, D.
    Foucault, C.
    Della Guardia, M.
    Hyvernat, H.
    Roger, P. -M.
    MEDECINE ET MALADIES INFECTIEUSES, 2016, 46 (07): : 365 - 371
  • [40] Detection of pneumococcal antigen in urine is not dependent on the nasopharyngeal pneumococcal load in children with community-acquired pneumonia
    Berger, Christoph
    Doesegger, Olivia
    Blessing, Gudrun
    Gunziger, Sibylle
    Nadal, David
    SWISS MEDICAL WEEKLY, 2007, 137 : 49S - 49S